PILOT STUDY OF THE RELATIONSHIP OF AMBIENT COPEPTIN TO THE AQUARETIC EFFECTS OF TOLVAPTAN IN PATIENTS WITH HEART FAILURE

Tolvaptan, an arginine vasopressin (AVP) antagonist, may be a novel therapy for congestive heart failure (CHF) but AVP activation is not uniform and results have been variable in previous trials of unselected CHF patients. Copeptin, c-terminal pre-provasopressin, reflects AVP activation. We